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Current and future perspectives on the
management of polypharmacy
Mariam Molokhia1 and Azeem Majeed2*
Abstract
Background: Because of ageing populations, the growth in the number of people with multi-morbidity and
greater compliance with disease-specific guidelines, polypharmacy is becoming increasingly common. Although
the correct drug treatment in patients with complex medical problems can improve clinical outcomes, quality of
life and life expectancy, polypharmacy is also associated with an increased risk of adverse drug events, some severe
enough to result in hospital admission and even death. Hence, having systems in place to ensure that medications
are started only when there is a suitable indication, ensuring patients are fully aware of the benefits and
complications that may arise from their treatment, and reviewing patients regularly to ensure their medication
regime remains appropriate, are essential.
Discussion: The development and rapid uptake of electronic patient records – particularly in primary care settings
where the majority of prescribing takes place – makes monitoring of patients more straightforward than in the
past; and allows identification of sub-groups of patients at particularly high risk of adverse drug events and
complications. It also facilitates ‘deprescribing’ the process by which medications are reviewed and stopped
if not clinically beneficial. In recent years, we have also seen the development of smartphone ‘apps’ to improve
communication between patients and healthcare professionals, improve people’s understanding of their
conditions and their treatment, and maintain a record of changes made to patient’s medication. In the longer
term, developments such as the introduction of artificial intelligence and clinical decision support systems
also have the potential to improve prescribing and minimise the risks from polypharmacy. Finally, there is
considerable scope to improve the quality of prescribing and reduce risks from poly-pharmacy using
non-medical groups such as pharmacists, specialist nurses and physician assistants.
Summary: Polypharmacy has increased in recent decades and will continue to increase as populations age
and the number of people with multiple long-term conditions increases. As with all areas of medicine, the
evidence-base in this area continues to evolve. Further trials on the impact on patients with polypharmacy of
new interventions such as technology-based solutions and the use of different professional groups are needed
to improve the evidence-base in this area.
Keywords: Polypharmacy, Multimorbidity, Patient safety
Background
Polypharmacy is the concurrent use of multiple medi-
cations by one individual. It is becoming increasingly
common in the United Kingdom and in other countries
as populations age, the number of people with long-
term conditions rises, and doctors come under increas-
ing pressure to follow evidence-based guidelines for
chronic disease management; such as those issued by
the National Institute for Health and Care Excellence
in England [1]. Traditionally, these guidelines have been
based on single diseases and have rarely considered
multimorbidity. Inevitably, therefore, older patients
who have co-existing medical problems may end being
prescribed several different drugs by their physicians.
For example, a patient with type 2 diabetes, hyperten-
sion and osteoarthritis may be prescribed one or more
oral hypoglycaemic agents, an angiotensin converting
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enzyme (ACE) inhibitor, other anti-hypertensive agents,
a statin, aspirin, and an analgesic.
The relative absence of up to date evidence-based
guidelines is a key limitation in the management of mul-
timorbidity and its associated polypharmacy. There have
been numerous ‘single-disease’ guidelines published by
many professional societies and government agencies.
Developers of guidelines such as the National Institute
for Health and Care Excellence are now recognising this
and are developing guidelines that consider the increas-
ing number of people who have more than one signifi-
cant long-term condition [2]. However, the development
of these new guidelines and their impact on clinical out-
comes and patient experience will take some time to
become apparent because of the lack of clinical trials in
patients with multi-morbidity. Randomised clinical trials
in the past have often had quite rigorous selection pro-
cedures that resulted in older, frailer patients with
multi-morbidity being excluded. These however are the
patients that are seen increasingly in clinical practice;
and who are most likely to be subject to polypharmacy.
In the absence of data on these patients from clinical
trials, an alternative method of generating evidence
about the benefits and risks of polypharmacy is to use data
from large clinical databases or patient registries [3].
Although the correct combination of drugs in patients
with complex medical problems can improve their
health status, clinical condition and quality of life, poly-
pharmacy also increases the risk of drug interactions
and side-effects; for example, hyponatraemia or postural
hypotension through the use of diuretics or antihyper-
tensive agents. These drug-induced adverse events can
sometimes be severe enough to necessitate hospital
admission (for example, postural hypotension could re-
sult in a fall leading to a fracture) and can occasionally
even result in death [4]. Even in milder cases, adverse
drug reactions and drug interactions can have a signifi-
cant effect on a patient’s quality of life. In this article, we
will review trends in polypharmacy and how clinicians
can try to ensure they maximise the benefits of prescrib-
ing and minimise the associated complications; particu-
larly in the increasing number of frail, elderly patients
that physicians are now seeing in health systems across
the world.
How do we define polypharmacy?
There is no standard definition of polypharmacy.
Although many studies on this topic simply report a
count of the number of prescription drugs, this is a
crude measure [5]. For example, basing the definition
of polypharmacy simply on the number of drugs a
patient is receiving does not take into account the ben-
efits that patients may receive from their medication
(Table 1). Moreover, the number of drugs that patients
receive has been steadily increasing for many years.
Hence, a drug count that might have been considered
high 20-30 years ago may no longer be considered high
now. For example, a study from Scotland reported that
the mean number of drugs received by patients in-
creased from 3.3 in 1995 to 4.4 in 2010; and the mean
number of drugs received by patients may well have in-
creased still further since then [6].
The same study also reported that the number of
patient receiving 5 or more medications and 10 or more
medications increased by 1.8-fold and 3.1-fold respect-
ively during the study period; and the percentage of
people aged 65 and over receiving 10 or more medica-
tions had reached 16.4% by 2010. A study from England
reported that 17% of patients in primary care were re-
ceiving between 5 and 9 medications and an additional
9.7% were receiving 10 or more medications [7]. Studies
from other countries have reported similar findings: an in-
crease in prescribing rates over time, as well as an increase
in the proportion of patients on 10 or more drugs.
Alternative measures of polypharmacy other than
simple counts include the number of potentially
inappropriate drugs or drug-combinations, based on
pre-defined criteria (such as the widely-used Beers cri-
teria or STOPP/START criteria) [8, 9]. More recently,
to help distinguish between ‘good’ and ‘bad’ polypharmacy,
the terms “potentially appropriate” and “potentially prob-
lematic polypharmacy” have been suggested. Appropriate
polypharmacy is defined as prescribing for a patient with
complex medical conditions or for multiple conditions in
circumstances where medicine use has been optimised or
where medicines are prescribed based on the best avail-
able evidence. Problematic polypharmacy is defined as
prescribing of multiple medications inappropriately or
where the patient does not receive the intended benefit of
the medication. A key aim of such tools is to identify po-
tentially inappropriate prescribing; particularly in frail,
older patients who are the group most at risk of adverse
events [10].
Table 1 Some sources of patient benefits and harms from
polypharmacy
Benefits Outcome
Improved disease management Reduced risk of disease
complications and mortality
Optimised medicines management Evidence based prescribing
Harms Consequences
Increased drug interactions Electrolyte disturbances;
potentiation of drug effects





Lack of monitoring Safety risks to patients
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Risks from polypharmacy
At age 65 years, around 8 years of the 20 remaining
years of life can be expected to be lived with polyphar-
macy. After age 75 years, more than half of the
remaining life expectancy will be spent with polyphar-
macy. Higher rates of prescribing are in turn associated
with higher rates of potentially unsafe prescribing and
rates of adverse events. The PRACtICe Study reported
that 30% and 47% of patients receiving 5 or more and
10 or more medications respectively had prescribing or
monitoring errors in the 12-month study period [7].
After adjusting for other factors, each additional medi-
cation increased the risk of an error occurring by 16%.
A Scottish study of patients in primary care thought
to be vulnerable to adverse drug events reported that
14% of patients had received a high-risk prescription
in the past year. The risk factor most strongly associ-
ated with high risk prescribing was the number of
drugs prescribed: patients on more than 10 medica-
tions had a nearly 3-fold increase in high-risk
prescribing compared with those receiving 1 or 2 med-
ications [11].
High risk groups
The risks from polypharmacy are higher in vulnerable
groups, including those with existing co-morbidities
such as diabetes and rheumatological diseases, and
older patients [12]. Patients living in care homes and
housebound patients are also at higher risk of compli-
cations from polypharmacy. The complications associ-
ated with polypharmacy can include adverse clinical
outcomes such as renal failure and falls leading to
fractures, as well as an increased risk of mortality [13].
There is also a financial impact on health systems
through outcomes such as an increase in urgent hos-
pital admissions and hospital readmissions [14]. In a
study of patients with rheumatoid arthritis, increasing
drug use was associated with more frequent acute hos-
pitalisations; patients in the highest drug use group
(≥10 drugs) had a more than 3-fold increase in the rate
of hospitalisation compared to those in the lowest
drug use group (0-5), even after adjustment for age
and sex. The risk of hospitalisation was even higher in
those taking steroids [15]. In developed countries,
older people will form an increasingly large proportion
of the population and this ‘aging’ of the population will
be associated with a parallel increase in the number of
people with long-term conditions such as hyperten-
sion, arthritis, diabetes and heart disease. Hence, poly-
pharmacy in at risk groups - and the elderly in
particular - will become an increasingly important
issue for patients, carers, clinicians, health systems
and societies.
Identifying patients with polypharmacy
Duerden and Avery, in their report for the King’s Fund,
outline a pragmatic approach to identifying patients with
polypharmacy and identifying ‘at risk’ patients using a
combination of patient characteristics and the number
of drugs prescribed [10]. This approach is based on prior
research showing an association between adverse health
outcomes and polypharmacy, and that this association is
more marked in patients with major illnesses. Duerden
and Avery recommend focusing on patients who are on
10 or more drugs; or patients receiving 5-9 drugs who
have other risk factors such as a major comorbidity (e.g.
diabetes or rheumatoid arthritis), have suffered previous
adverse drug reaction, or are from a vulnerable group
(e.g. people living in care homes or with a learning
disability). Another UK study reported that the three
commonest drugs linked to adverse drug reactions that
resulted in hospital admission were non-steroidal anti-
inflammatory agents, diuretics, and warfarin [16]. Stud-
ies such as this can guide clinicians as to which patients
to focus on so they can identify those who may be at
highest risk from the complications associated with
polypharmacy.
The rapid development, implementation and use of
electronic patient records in primary care greatly simpli-
fies the process of identifying patients with polyphar-
macy. In the United Kingdom for example, there is now
100% uptake of electronic patient records in general
practice, with high rates of use also seen in many other
developed countries. Searches to identify patients with
polypharmacy that might have taken hours (or even
days) to complete with paper-based records can now be
carried out in minutes. As well as identifying patients
based on the number of drugs they are taking, it is
straightforward to also include variables such as age,
drug group or laboratory test results into such searches.
This can allow physicians to identify high risk groups
who would benefit from medication reviews and closer
monitoring of their prescribing and their illnesses (for
example, those or warfarin or with raised creatinine
levels). In the future, linkage of primary care records
with hospital admission records can further improve this
process by allowing the identification of individuals who
have had an acute hospital admission from an adverse
drug reaction or a drug interaction.
Managing polypharmacy in patients with multimorbidity
In 2016. England’s National Institute for Health and
Care Excellence published guidance on the clinical as-
sessment and management of patients with multimor-
bidity (defined as the presence of two or more long-term
health conditions). The guidance emphasizes the need to
deliver care in a way that considers multimorbidity and
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any associated frailty in patients. This includes, for ex-
ample factors, such as:
 how the person’s health conditions and their
treatments interact and how this affects quality of life
 the person’s individual needs, preferences for
treatments, health priorities, lifestyle and goals
 the benefits and risks of following recommendations
from guidance on single health conditions
 improving quality of life by reducing treatment burden,
adverse events, and episodes of unplanned care
The NICE guidance recommends that clinicians con-
sider evidence of likely benefits and harms for the indi-
vidual patient and outcomes important to the patient.
This could be for example through the use of a screen-
ing tool (for example, the STOPP/START tool in older
people) to identify medicine-related safety concerns and
medicines the person might benefit from but is not cur-
rently taking. The important of reviewing patients to
monitor the effects of any changes made to prescribing
are also emphasised, which would include the need to
whether any further changes to treatments are needed
(including restarting a treatment). The importance of
shared decision-making is also a key part of this guid-
ance; this is particularly important in people with frailty
or limited life expectancy who have less capacity to
benefit from pharmacological interventions.
Risk prediction tools
One method of facilitating guidance on managing
patients with polypharmacy would be through the
development and application ‘risk prediction tools’ for
quantifying the risk of adverse drug reactions. A sys-
tematic review published in 2014 evaluated the quality
of validated risk-prediction tools for adverse drug reac-
tions in people over 65 years of age [17]. The authors
of the review identified four main tools [18–21]. How-
ever, all the risk prediction tools had limitations and
hence their performance was generally modest [17]. In
addition to their relatively weak performance, these
tools were all developed using data for hospital inpa-
tients and we do not therefore know how well they
would perform for patients in ambulatory or primary
care settings. Further research in this area should there-
fore focus on developing risk prediction models that
can be used in out-of-hospital settings as this is where
the majority of prescribing for patients with long-term
conditions takes place. Another key finding from this
review is that many variables contribute to the risk of
adverse drug reactions and it is therefore difficult to de-
velop robust risk prediction tools. Hence, although sev-
eral risk tools exist, none currently have sufficient
predictive value for use in routine clinical practice [22].
Consequently, it may therefore be some time before we
risk scores for patients with polypharmacy that are for
example as widely used as tools for assessing cardiovas-
cular risk, such as QRISK in the UK [23, 24].
The use of electronic patient records for ‘secondary’
uses such as this that are not directly for the care of an
individual patient does bring ethical, political and tech-
nical challenges. In England, the government an-
nounced in July 2016 that the care.data programme
that was designed to harness the potential of the
electronic patient records that the NHS holds for work
like this was to be abandoned [25]. The care.data
programme – although it promised many benefits for
research and quality improvement – ran into consider-
able opposition from clinicians, patient groups and the
public because of concerns about the ethics of ‘harvest-
ing’ data from people’s electronic health records with-
out their explicit consent; and because of the potential
security issues and threats to confidentiality from stor-
ing such a large amount of personal data in one place.
The key lessons from this episode for health systems in
other countries are that patients and the public need to
be convinced about the benefits of use of their data for
secondary purposes not directly related to their clinical
care; and that smaller, less ambitious, more targeted
projects in this area are more likely to receive public
support and to be implemented.
Evidence base on optimising prescribing
Two systematic reviews are relevant here, one which
looked at improving outcomes for people with multiple
chronic conditions’ and the other at improving the ap-
propriate use of polypharmacy in older people. Smith et
al. identified 18 relevant randomised controlled trials of
interventions that aimed to improve the management of
people with multimorbidity and common comorbidities
in primary care and community settings [26]. They re-
ported that there was a lack of evidence about the
effectiveness of interventions for people with multimor-
bidity because of the relatively small number of trials
conducted on this topic thus far, and that the trials that
had been carried out has mixed findings. There was
some evidence though of improved health outcomes if
interventions can be targeted at risk factors such as de-
pression or specific functional difficulties in people with
multimorbidity. Cooper et al. identified 12 studies (of
which 10 were randomised controlled trials) of interven-
tions that aimed improve the use of polypharmacy in
older people [27]. There were a range of interventional
strategies deployed and some evidence that these led to
more appropriate polypharmacy (based on lower levels
of inappropriate prescribing). However, it was not clear
if these interventions led to clinically important
Molokhia and Majeed BMC Family Practice  (2017) 18:70 Page 4 of 9
improvements (for example, a reduction in emergency
hospital admissions).
Optimising the use of medicines
Given the risks from polypharmacy, improving the use
of medicines – and reducing the risks to patients from
inappropriate or unsafe prescribing – should be a pri-
ority for health systems [28]. All prescribers need to
carefully consider the potentials costs as well as the
benefits of treatment before starting a drug; and be
aware of the risks of over-treatment, drug interactions
and adverse drug reactions. Until recently, health
systems and professional societies have focused on
producing single-disease guidelines and we are only
now seeing some progress in developing guidelines for
managing patients with multimorbidity. Tools to pro-
mote shared decision-making by doctors and patients
are also a relatively new development. In recent years,
we have seen the introduction of initiatives such as the
International Patient Decision Aids (IPDAS) collabor-
ation, the Dutch Decision Aids Implementation
Programme and the Center for Informed Choice in the
USA [29].
Prescribers also need to have systems in place for
monitoring prescribing and reviewing patients regularly.
The use of electronic patient records can facilitate this
monitoring, as can the use of other professional groups
such as pharmacists, specialist nurses and physician as-
sistants to support doctors in this monitoring and
reviewing role. In England, the General Practice Forward
View aims to provide investment to recruit such non-
medical professional groups to support general practi-
tioners, thereby freeing up physicians’ time to focus on
more complex patients [30].
An intervention using data from linked electronic
medical records showed that intervening in primary care
practices can significantly reduce rates of high-risk pre-
scribing of drugs [28]. The study, which was carried
out 33 medical practices with a registered population
of around 200,000 patients in the Tayside region of
Scotland, also showed that the change in prescribing
patterns can lead to significant reductions in related
emergency admissions to hospital. The study team ex-
amined patients’ exposure to high-risk prescribing of
non-steroidal anti-inflammatory drugs or antiplatelet
agents. This included prescriptions to people with
kidney disease or heart failure, or prescribing to people
taking anticoagulant drugs like warfarin. The 48-week
intervention comprised professional education, inform-
atics to facilitate reviews of patient treatment, and
small financial incentives for practices to review pa-
tients. The interventions led to a 37% reduction in
high-risk prescribing, and this improvement was sus-
tained after financial incentives to review patients were
withdrawn. There was also an associated reduction the
rate of hospital admissions for gastrointestinal ulcer or
bleeding, and for heart failure.
Vulnerable populations
People living in care homes are perhaps the frailest and
most vulnerable group in the community. They are
particularly likely to be on multiple prescription medi-
cations and are also at high risk of complications from
inappropriate prescribing. A systematic review of stud-
ies that aimed to improve prescribing for people living
in care homes concluded that there is no one interven-
tional strategy that has proved to be effective [31]. The
interventions examined included staff education,
pharmacist-led medication reviews, multi-disciplinary
team meetings, and computerised clinical decision
support systems. There was some evidence that a
multi-faceted approach to optimising prescribing that
used more than one intervention was more likely to be
successful than a single intervention. Given the lack of
evidence, it is clear that this is an area that would
benefit from additional research. In particular, the use
of computerised clinical decision support systems that
can use the information held in electronic patient re-
cords is an avenue that should be explored. However,
thus far, computerised decision support systems have
provided only limited evidence of benefit and consid-
erable more developmental work needs to be done to
harness their potential [32, 33]. Another systematic
review of interventions targeting older adults living in
the community reached similar conclusions. The inter-
ventions examined in the review were organizational
(pharmacist interventions), professional (computerized
clinical decision support systems), and multifaceted
approaches. The interventions did appear beneficial in
reducing potentially inappropriate prescribing, but the
range of effect sizes was modest, and it is unclear
whether such interventions can result in clinically sig-
nificant improvements in patient outcomes. As with
many such studies, the authors concluded this was an
area where more research was needed [34].
Artificial intelligence and cognitive computing
In the longer-term, it is possible that we could see the use
of automated analytical techniques, artificial intelligence
technologies and ‘deep learning methods’ such as those
developed by companies such as DeepMind could also be
applied in this area [35]. One example of this is research
in this area is a project to improve the detection of acute
kidney injury, many cases of which are drug-induced, and
which is a major cause of morbidity and mortality globally.
Using techniques to integrate and analyse clinical data
from a range of sources, DeepMind aims to automatically
identify patients with acute kidney injury and notify their
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clinicians promptly; thereby aiming to detect acute kidney
injury earlier and giving clinicians the opportunity to
change a patient’s clinical management [36]. Similar
methods could also be used to risk stratify patients to
identify those at higher risk of complications, thus giving
their clinical teams the option to modify their patients’
treatment to reduce this excess risk [37]. A related area is
the development of ‘cognitive computing’. This is being
pioneered by companies such as IBM, which is using its
Watson Health Platform to support clinicians to optimise
treatment and prescribing decisions for patients. The
Watson platform is based on natural language processing
and machine learning from very high volumes of unstruc-
tured clinical data. Although technologies such as artificial
intelligence and cognitive computing are still in a very
early phase of development, considerable financial invest-
ments are being made in this field by companies such as
Google and IBM. It seems inevitable therefore that in fu-
ture years such technologies will become increasingly
commonplace in healthcare settings, radically changing
the way in which doctors and other health professionals
work; as well as giving patients more support in the man-
agement of their long-term conditions and in optimising
their health [38].
Medicine reconciliation
Another key area in polypharmacy is ‘medicines recon-
ciliation’: ensuring that when patients are discharged
from hospital, particularly after an acute admission, sys-
tems are in place for rapidly communicating any
changes in medication, and why these changes took
place, to primary care teams. Prior research has shown
that the discharge summaries received by primary care
teams are often inaccurate or lacking key information;
and this is an area where better collaboration is needed
between primary care and secondary care teams to de-
velop safer discharge policies and reduce the risk of
medication-related errors. A systematic review and
meta-analysis of medicines reconciliation published in
2016 showed that medicines reconciliation can reduce
adverse drug event-related attendances at emergency
departments and readmissions to hospital [39].
Another key step in reducing risks from polypharmacy
is to improve the discharge process for patients [40, 41].
This would include:
 Ensuring that discharge arrangements are discussed
with patients, family members and carers; and that
they are given a copy of the discharge summary.
 Adequate coordination between the hospital,
community health services, general practices, and
the providers of social care services.
 There is a follow-up after discharge of patients at
high risk of complications or readmission - either in
person or by telephone - to ensure that the
discharge arrangements are working well.
 Medicines reconciliation is carried out. This is the
process of verifying patient medication lists at a
point-of-care transition, such as hospital discharge,
to identify which medications have been added,
discontinued, or changed from pre-admission
medication lists.
 Ensuring that any outstanding test results at
discharge are obtained and passed on to primary
care teams; and ensuring there are clear
arrangements for carrying out and acting on any
proposed post-discharge tests.
Management of side effects
Side effects from drugs are common, with the highest
rates seen in patients with polypharmacy. Previous re-
search has shown that many patients do not report the
side effects of their drugs to their physicians; and when
they do inform their physicians, these side effects are
sometimes not recorded in patients’ medical records or
reported to regulatory authorities. Prior research has
shown that physicians prescribing new medications often
do not convey important medication-related information
to their patients and this is an area of practice that needs
to be improved. A physician-targeted educational session
in the USA improved the content of and enhanced pa-
tient ratings of physician communication about new
medication prescriptions [42]. Education of patients in
turn can improve their reporting of side effects to their
physicians. New smartphone applications aimed at pa-
tients with long-term conditions have the potential to
help in the recording and management of drug side-
effects but their use requires further evaluation [43]; as
do systems for allowing patients to self-report drug side
effects to national pharmaceutical regulatory organisa-
tions [44].
Involving patients
A key component of addressing the risks associated with
polypharmacy is to ensure that patients are fully
involved in the decision to start a drug; and also in
monitoring their use of medication to ensure appropri-
ate adherence to their prescribed drug regime. This
will include briefing patients about the risks of their
medication, as well as its benefits; the importance of
undergoing a regular medication review; reporting any
adverse events promptly to their physician; and dis-
cussing with patients ‘reminder’ systems such as
dosette boxes to ensure they take their medication at
the right time and dosage. The use of polypills that
allow patients to take one pill in place of several could
also improve patients’ use of their medication [45].
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One negative effect of giving patients ‘too much’ infor-
mation however is that that they may then be discour-
aged from taking a drug because of concerns about its
side-effects. Tools to promote shared decision-making
can help overcome such concerns and improve patients’
adherence to their proposed management plan by pro-
viding information on the benefits and risks of drugs in
a format patients can understand more easily [46].
Awareness of the relationship between patients, their
social networks, and health services as in the ‘Burden
of Treatment’ model described by May and colleagues
can also help approve patient’s adherence to their medi-
cation [47].
Another area where shared decision making can help
in is ‘deprescribing’, the process of planned and super-
vised tapering or ceasing of inappropriate medicines
[48]. Deprescribing is particularly important in frail,
older patients or in patients with limited life expect-
ancy in whom the inappropriate use of medication is
widespread, and who are at high risk of adverse drug
reactions, hospitalisation and death. Optimization of
medication in these patient groups can be challenging
but can yield considerable benefits – for both patients
and health systems – through appropriate use of depre-
scribing. Through a review of previously proposed
deprescribing processes, Reeve and colleagues developed a
patient-centred deprescribing process, using a five-step
cycle that included a comprehensive medication history,
identifying potentially inappropriate medications, deter-
mining whether the potentially inappropriate medication
can be stopped, planning the withdrawal process; along
with provision of monitoring, support and documenta-
tion.[Reeve] This approach shows promise and now needs
to be tested in a wider range of clinical settings.
In recent years, we have also seen the development of
smartphone ‘apps’ such as the My Medication Passport
to improve communication between patients and health-
care professionals, improve people’s understanding of
their conditions and their treatment, and maintain a rec-
ord of changes made to patient’s medication [49]. These
smartphone-based tools do show promise – as does
giving patients online access to their electronic medical
records - but such technologically-based interventions
need rigorous evaluation to determine if clinicians, pa-
tients and carers will use them, and to ensure that they
are cost-effective [50]. For example, a review of smart-
phone apps for patients with asthma found a number
of errors in many of them and a lack of compliance
with current clinical guidelines [43].
One important limitation of the use of information
technology based tools is that older patients – who are
the main target for interventions to improve prescribing
- are the least likely to use them. This will change over
time as devices such as smartphones become more
widely used but for now, clinicians will also have to use
paper-based tools for such patients if they are unwilling
or uncomfortable with using information technology-
based tools. We should also not also overlook that work
to improve prescribing regimes and reduce the problems
associated with inappropriate polypharmacy will require
considerable levels of inter-professional working, sup-
port from patients; and substantial behavioural change
from both clinicians and patients.
Personalised medicine
The key message from prior research on polypharmacy
is the need to manage the risks and benefits of drug
treatment. This is an area where ‘personalised medicine’
approaches may help. In recent decades, healthcare has
gradually progressed from being reactive to care that is
predictive, preventive, personalized and participatory
[51]. This new approach to healthcare will eventually
provide patients and physicians with personalised infor-
mation about each individual’s unique health experience.
This information can help personalise care to each
person’s unique characteristics. This approach can be
further enhanced through support from ‘digital patient
communities’ that allow patients to interact with other
patients with similar long-term conditions and learn
from the experience of other patients [52]. Such digital
communities are now common for many conditions and
are a particularly useful source of support for those pa-
tients with very rare conditions.
Conclusions
Polypharmacy, however it is defined, has increased in
recent decades and will continue to increase as popula-
tions age and the number of people with long-term
conditions also increases. For high risk individuals and
drug classes, targeted reviews and appropriate regular
monitoring can help address the increased risks of
adverse events from polypharmacy. Non-medical pro-
fessionals such as pharmacists, specialist nurses and
physician assistants have a key role to play in this area
as does making full use of the benefits offered by elec-
tronic patient records. Clinicians also need to ensure
that patients are fully involved in decisions about their
prescribing and in the monitoring of their medical
problems. Simple aids such as dosette boxes can help
patients use their medication appropriately.
The development of smartphone apps, clinical-
decision support systems using newly-developed artifi-
cial intelligence technology, and giving patients online
access to their electronic medical records, also show
promise to improve the safety and appropriateness of
prescribing, and improve patients’ knowledge of their
medication. In this era of personalised medicines, we
should aim to balance individual risks and benefits for
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our patients using all the tools available to us; and im-
plement appropriate mechanisms for monitoring and
reviewing prescribing decisions in our patients. As with
all areas of medicine, the evidence-base in this area has
many gaps and continues to evolve. Further trials on
the impact on patients with polypharmacy of new inter-
ventions such as technological solutions and the use of
different professional groups and multi-disciplinary
working are therefore needed to give patients and clini-





King’s College London and Imperial College London are grateful for support
from the NIHR Collaboration for Leadership in Applied Health Research &
Care programme and the NIHR Biomedical Research Centre programme.
These funders had no role in the preparation of the article. The views
expressed in this article are those of the authors.
Availability of data and materials
No supporting data available.
Authors’ contributions
MM wrote the first draft of the article, which was then revised by AM. Both
authors contributed to the review of the literature and approved the final
version of the article.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Department of Primary Care and Public Health Sciences, King’s College
London, London SE1 3QD, UK. 2Department of Primary Care and Public
Health, Imperial College London, W6 8RP, London, UK.
Received: 30 January 2017 Accepted: 28 May 2017
References
1. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide
of polypharmacy and drug-drug interactions: population database analysis
1995–2010. BMC med. 2015;13:74.
2. Multimorbidity: clinical assessment and management. https://www.nice.org.
uk/guidance/indevelopment/gid-cgwave0704. Accessed 31 May 2017.
3. Azoulay L, Filion KB, Platt RW, et al. Association between Incretin-based drugs
and the risk of acute pancreatitis. JAMA Intern med. 2016;176(10):1464–73.
4. Fried TR, O'Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK. Health
outcomes associated with polypharmacy in community-dwelling older
adults: a systematic review. J am Geriatr soc. 2014;62:2261–72.
5. Gillette C, Prunty L, Wolcott J, Broedel-Zaugg K. A new lexicon for
polypharmacy: implications for research, practice, and education. Res soc
Adm Pharm. May–June 2015;11(3):468–71.
6. Guthrie B, Makubate B. The rising tide of polypharmacy and potentially
serious drug interactions 1995–2010: repeated cross sectional analysis of
dispensed prescribing in one region. Primary Health Care Research &
Development. 2012;13: S1: 45 2E.2.
7. Avery A, Barber N, Ghaleb M, Dean Franklin B, Armstrong S, Crowe S, et al.
Investigating the prevalence and causes of prescribing errors in general
practice: the PRACtICe study. General Medical Council [Online] Available
at: http://www.gmc-uk.org/about/research/25043.asp. 2012b; accessed on
23 May 2016
8. Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (screening tool of
older Person’s prescriptions) and START (screening tool to alert doctors to right
treatment). Consensus validation. Int J Clin Pharmacol Ther. 2012;46:72–83.
9. American Geriatrics Society 2015 Beers Criteria Update Expert Panel.
American Geriatrics Society 2015 updated Beers criteria for potentially
inappropriate medication use in older adults. J am Geriatr soc. 2015;63(11):
2227–46.
10. Duerden M, Avery T, Payne R. Polypharmacy and medicines optimisation.
London: Making it safe and sound. King’s Fund; 2013.
11. Guthrie B, McCowan C, Davey P, Simpson CR, Dreischulte T, Barnett K. High
risk prescribing in primary care patients particularly vulnerable to adverse
drug events: cross sectional population database analysis in Scottish general
practice. British Medical. 2011;342:d3514.
12. Stocks SJ, Kontopantelis E, Akbarov A, Rodgers S, Avery AJ, Ashcroft DM.
Examining variations in prescribing safety in UK general practice: cross sectional
study using the clinical practice research Datalink. Bmj. 2015;351:h5501.
13. Tiihonen J, Suokas JT, Suvisaari JM, MD, PhD; et al. Polypharmacy with
antipsychotics, antidepressants, or benzodiazepines and mortality in
schizophrenia. Arch gen Psychiatry 2012;69(5):476-483.
14. Alarcón T, Bárcena A, González-Montalvo JI, Penãlosa C, Salgado A. Factors
predictive of outcome on admission to an acute geriatric ward. Age
Ageing. 1999;28(5):429–32.
15. Filkova M, Ibrahim F, Norton S, Scott D, Mant T, Cope A, Molokhia M,
Galloway J. Polypharmacy, although not combination DMARD therapy in
rheumatoid arthritis patients is associated with increased hospital admission
risk. European League against Rheumatism EULAR Abstract 15-3604. 2015.
16. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. ADRs
as cause of admission to hospital: prospective analysis of 18 820 patients.
Bmj. 2004;329:15–9.
17. Stevenson JM, Williams JL, Burnham TG, Prevost AT, Schiff R, Erskine SD, et
al. Predicting adverse drug reactions in older adults; a systematic review of
the risk prediction models. Clin Interv Aging. 2014;9:1581.
18. McElnay JC, McCallion CR, Al-Deagi F, Scott MG. Development of a risk model
for adverse drug events in the elderly. Clin Drug Invest. 1997;13:47–55.
19. Tangiisuran B. Predicting adverse drug reactions in the hospitalised elderly
[PhD thesis]. Brighton: University of Sussex; 2009.
20. Onder G, Petrovic M, Tangiisuran B, et al. Development and validation of a
score to assess risk of adverse drug reactions among in-hospital patients 65
years or older: the GerontoNet ADR risk score. Arch Intern med. 2010;170:
1142–8. [PubMed]
21. Trivalle C, Burlaud A, Ducimetière P. IMEPAG group. Risk factors for adverse
drug events in hospitalized elderly patients: a geriatric score. European
Geriatric Medicine. 2011;2(5):284–9.
22. Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older
adults. Therapeutic Advances in Drug Safety. 2016 Feb;7(1):11–22.
23. NICE. Multimorbidity: clinical assessment and management. https://www.
nice.org.uk/guidance/ng56
24. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A,
et al. Predicting cardiovascular risk in England and Wales: prospective
derivation and validation of QRISK2. Bmj. 2008;336:1475–82.
25. Limb M. Controversial database of medical records is scrapped over security
concerns. Bmj. 2016;354
26. Smith SM, Wallace E, O'Dowd T, Fortin M. Interventions for improving
outcomes in patients with multimorbidity in primary care and community
settings. Cochrane Database Syst Rev. 2016;Issue 3. Art. No.: CD006560.
DOI: 10.1002/14651858.CD006560.pub3.
27. Cooper JA, Cadogan CA, Patterson SM, et al. Interventions to improve the
appropriate use of polypharmacy in older people: a Cochrane systematic
review. BMJ Open. 2015;5:e009235. doi:10.1136/bmjopen-2015-009235.
28. Dreischulte T, Donnan P, Grant A, Hapca A, McCowan C, Guthrie B. Safer
prescribing—a trial of education, informatics, and financial incentives. N
Engl J med. 2016;374:1053–64.
29. Barry MJ, Edgman-Levitan S. Shared decision making — the pinnacle of
patient-centered care. N Engl J med. 2012;366:780–1.
30. NHS England. General Practice Forward View.
https://www.england.nhs.uk/ourwork/gpfv/. Acessed 31 May 2017.
31. Loganathan M, Singh S, Franklin BD, Bottle A, Majeed A. Interventions to
optimise prescribing in care homes: systematic review. Age Ageing. 2011;
40(2):150–62.
Molokhia and Majeed BMC Family Practice  (2017) 18:70 Page 8 of 9
32. Bryan C, Boren SA. The use and effectiveness of electronic clinical decision
support tools in the ambulatory/primary care setting: a systematic review of
the literature. Inform Prim Care. 2008;16:79–91.
33. Yourman L, Concato J, Agostini JV. Use of computer decision support
interventions to improve medication prescribing in older adults: a
systematic review. Am J Geriatr Pharmacother. 2008;6:119–29.
34. Clyne B, Fitzgerald C, Quinlan A, Hardy C, Galvin R, Fahey T, et al.
Interventions to address potentially inappropriate prescribing in
community-dwelling older adults: a systematic review of randomized
controlled trials. J am Geriatr soc. 2016;64(6):1210–22.
35. Silver D, Huang A, Maddison CJ, Guez A, Sifre L, van den Driessche Get al.
Mastering the game of go with deep neural networks and tree search.
Nature 2016;529:484–489.
36. DeepMind. Acute Kidney Injury. https://deepmind.com/applied/deepmind-
health/streams/. Accessed 31 May 2017.
37. Obermeyer Z, Emanuel EJ. Predicting the future — big data, machine
learning, and clinical medicine. N Engl J med. 2016;375:1216–9.
38. Keim B. Paging Dr Watson: Artificial Intelligence as a Prescription for Health
Care. https://www.wired.com/2012/10/watson-for-medicine/. Accessed 31
May 2017.
39. Mekonnen AB, McLachlan AJ, Brien JE. Effectiveness of pharmacist-led
medication reconciliation programmes on clinical outcomes at hospital
transitions: a systematic review and meta-analysis. BMJ Open. 2016;6:e010003.
40. Hospital discharge and readmission. http://www.uptodate.com/contents/
hospital-discharge-and-readmission. Accessed 31 May 2017.
41. Majeed A. Improving discharge planning in NHS hospitals. http://medical-
centre.blogspot.co.uk/2014/01/improving-discharge-planning-in-nhs.html.
Accessed 31 May 2017.
42. Tarn DM, Paterniti DA, Orosz DK, Tseng C-H, Wenger NS. Intervention to
enhance communication about newly prescribed medications. Ann Fam
med. 2013;11(1):28–36.
43. Huckvale K, Car M, Morrison C, Car J. Apps for asthma self-management: a
systematic assessment of content and tools. BMC med. 2012;10:144.
44. Basch E. The missing voice of patients in drug-safety reporting. N Engl J
med. 2010;362:865–9.
45. Wise J. Polypill holds promise for people with chronic disease.
http://www.who.int/bulletin/volumes/83/12/news11205/en/. Accessed 31
May 2017.
46. The Health Foundation. Shared decision making. http://goo.gl/QRD71j.
Accessed 31 May 2017.
47. May CR, Eton DT, Boehmer K, Gallacher K, Hunt K, MacDonald S, et al.
Rethinking the patient: using burden of treatment theory to understand the
changing dynamics of illness. BMC Health Serv res. 2014;14:281.
48. Jansen J, Naganathan V, Carter SM, McLachlan AJ, Nickel B, Irwig L, et al.
Too much medicine in older people? Deprescribing through shared
decision making. Bmj. 2016;353
49. My Medication Passport. http://clahrc-northwestlondon.nihr.ac.uk/resources/
mmp. Accessed 31 May 2017.
50. Black AD, Car J, Pagliari C, et al. The impact of eHealth on the quality and
safety of health care: a systematic overview. PLoS med. 2011;8:e1000387–7.
51. Flores M, Glusman G, Brogaard K, Price ND, Hood L. P4 medicine: how
systems medicine will transform the healthcare sector and society.
Personalized Medicine. 2013;10(6):565–76.
52. Richards T, Coulter A, Wicks P. Time to deliver patient centred care. Bmj.
2015 Feb 10;350:h530.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Molokhia and Majeed BMC Family Practice  (2017) 18:70 Page 9 of 9
